April 5, 2007 -- A bidding war has broken out over Biosite. Inverness Medical Innovations offered $90 per share, trumping an $85 per share bid from Beckman Coulter; Schering-Plough announced approval in China of Pegintron for hepatitis B; Crucell received a 1.7 million euro grant from a European commission to develop an avian flu vaccine; and Trimeris will further cut its workforce. Biotech ended the trading week with a solid gain (markets will be closed tomorrow for Good Friday). The Centient Biotech 200™ climbed 47 points to 3995, an increase of 1.18%. More details...
